New Dotmatics solution to streamline your antibody discovery process

Luma Antibody & Protein Engineering: First in a Series of Custom-Designed Multimodal Solutions

The R&D landscape has shifted rapidly from small molecule therapeutics to more complex treatments like antibodies, RNA-based medicines, cell & gene therapy, and combination treatments. Each therapy type involves distinct yet interconnected processes, requiring scientific research organizations to manage vast and evolving volumes of diverse data. This complexity, along with challenges like siloed data and rigid workflows, can hinder R&D progress and reduce productivity.

The Luma Antibody & Protein Engineering solution, built on the new Geneious Luma platform, is designed to address these challenges. It streamlines antibody discovery and development—especially for monoclonal and multispecific antibodies—by enabling simple integration of data, teams, and experimental phases. Powered by trusted tools like Geneious and GraphPad Prism, this platform is transforming biologics R&D.

Researchers can now streamline workflows from planning and in-silico design to wet lab production, validation, and data analysis, all within a unified AI-native platform.

Working in Harmony Within a Single Platform

The solution is built on the Dotmatics Luma scientific intelligence platform, which accelerates AI-powered data management and workflow automation by integrating data, teams, and experimental phases for researchers working on antibody discovery and other therapeutic modalities.

The solution leverages functionality from Dotmatics' scientific software products, allowing researchers to use familiar tools and creating a more cohesive and collaborative environment without data silos. The following tools are composed within Luma as part of the Antibody & Protein Engineering solution:

• ​Geneious Luma: Analyze and visualize DNA, RNA, and protein sequences. Access antibody discovery and screening capabilities, annotate and filter sequences, design constructs, and use adaptive workflows for cloning, expression, and purification.
• ​BioGlyph: Supports the design and generation of multispecific antibody formats and molecules, and runs predictive machine learning models to evaluate and rank potential candidates.
• ​Prism Luma: Use GraphPad Prism for antibody assay development and screening, with native normalization and pre-processing of results and contextual linking between assay results, registered materials, and experimental context.
• ​Byos and Byosphere Luma: Analyze protein structures and behaviors, integrate insights into predictive machine learning models, and curate, interrogate, and share information from the analytical lab.
• ​Luma Lab Connect: Streamline data collection from various lab instruments with automated data ingestion, auto-associating instrument results with workflow steps, materials, and endpoint data.
• ​Flow Luma: Evaluate molecular properties of antibody candidates and phenotype their therapeutic outcomes with OMIQ, a modern flow cytometry solution.

Filling Critical Gaps in the End-to-End Workflow

The Luma Antibody & Protein Engineering solution addresses major pain points in R&D, including:

• ​Multimodal Registration: Versioned, entity-specific, and extensible registration models driven by linked ontologies allow for scientific depth and precision. Registration happens automatically and asynchronously, tracking and storing experimental and product-related information throughout R&D. If a synthesized molecule does not match the design, Luma can modify the linked registered entity without losing lineage or context.
• ​Unified Results: All relevant project data—molecule designs, characterization data, assay data, endpoint data, and registered materials—are correlated and unified into normalized data structures and customizable dashboards. This enables quick decision-making about which antibodies to advance, eliminating hours of manual data wrangling.
• ​Customer Apps: Customers can extend Dotmatics Luma apps or create their own low-code apps to contextualize, flow, and correlate data from disparate sources, with scientifically smart dashboards and visualizations. Data integration options include REST, GraphQL, and JDBC.
• ​Artificial Intelligence: Luma includes generative and predictive ML capabilities for dry lab and wet lab tasks. Assistive GenAI accelerates data introspection, summarization, and visualization. Domain-specific AI supports protein prediction, flow cytometry autogating, and other scientific models. Composite AI enables the use of multiple models or datasets for higher order model training, selection, and execution.

Planned Solutions in Drug Discovery and Beyond

Dotmatics plans to release additional multimodal Luma solutions throughout 2025 and beyond. The Antibody & Protein Engineering solution is the first in a new series of Luma Multimodal R&D Solutions designed to address urgent R&D needs.

Upcoming solutions will target CAR-T cell discovery, siRNA, antibody-drug conjugates (ADCs), CRISPR therapeutics, and vaccine discovery. These will include applications like GraphPad Prism, Geneious, OMIQ, Protein Metrics, and FCS Express, all composed to work harmoniously within Luma. This approach allows researchers to use familiar tools while eliminating data and process silos.

Dotmatics also plans to extend Luma's use case into broader scientific domains, supporting researchers across industries such as material science, chemistry, industrial biotech, and agritech. Every solution built on the Luma platform will provide a cohesive user experience and smooth work and data flows, delivering a scalable platform that fosters innovation.

Embrace the Future of Therapeutic Research

Learn more about the Luma Antibody & Protein Engineering solution to see how Luma can transform R&D processes by bridging bench science with in silico innovation.

Visit the Dotmatics blog for updates as additional Luma solutions are previewed, further expanding the capabilities of the Luma Scientific Intelligence Platform.